About CytoMed Therapeutics Limited - Ordinary Shares (GDTC)

For CytoMed Therapeutics Limited - Ordinary Shares (GDTC), the 52-week high is $5.5, which is 161.9% from the current price. The 52-week low is $1.2, the current price is 75% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

The current price per share for CytoMed Therapeutics Limited - Ordinary Shares (GDTC) is $2.1. The stock has seen a price change of -$0.28 recently, indicating a -13.21% change. This reflects the stock's recent market performance and investor sentiment.

CytoMed Therapeutics Limited - Ordinary Shares (GDTC) has shown an average price growth of -6.65% over the past three years. It has received a score of 6 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying CytoMed Therapeutics Limited - Ordinary Shares as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

As of the latest data, CytoMed Therapeutics Limited - Ordinary Shares (GDTC) has a year-to-date price change of -52.38%. Over the past month, the stock has experienced a price change of -1.41%. Over the last three months, the change has been 20.69%. Over the past six months, the figure is -0.94%.

CytoMed Therapeutics Limited - Ordinary Shares (GDTC) has a net income of -$4.13M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -735.97% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 5.73%, providing insight into the company's sales performance and growth. The gross profit is $381.92K. Operating income is noted at -$2.91M. Furthermore, the EBITDA is -$2.33M.

CytoMed Therapeutics Limited - Ordinary Shares (GDTC) has a market capitalization of $25.09M. The average daily trading volume is 2.1, indicating the stock's liquidity and investor engagement.